Compare Johnson & Johnson (JNJ) vs KeyCorp (KEY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs KeyCorp — how do they compare? Johnson & Johnson trades at $256.46 (market cap $622.84B), while KeyCorp trades at $20.14 (market cap $21.16B). The key difference: Johnson & Johnson is far larger — about 29.4× KeyCorp's market cap, and KeyCorp pays the higher dividend (4.14%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and KeyCorp for 66 Days on average.
| JNJ | KEY | |
|---|---|---|
Market Cap | $622.84B | $21.16B |
Volume | 5,277,426 | 16,207,672 |
Sector | Health | Financials |
52-Week High | $278.43 | $23.99 |
52-Week Low | $186.00 | $16.78 |
Typical Hold Time | 129 Days | 66 Days |
Enterprise Value | $651.12B | $34.34B |
Dividend Yield | 2.07% | 4.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $258.45, up 1.44% today, with a bearish technical signal but strong fundamentals including a 21.48% net income margin and consistent earnings beats. The stock is supported by a diversified healthcare portfolio and a recent dividend declaration of $1.34 payable in September 2026. Revenue growth is projected to reach $97.9B in 2026, though net income is expected to moderate. Analyst consensus is bullish with a $286.53 price target, but technical indicators show resistance near $260.
JNJ presents a solid long-term investment opportunity due to its robust profitability, high ROE of 25.74%, and defensive sector positioning. Risks include increasing debt-to-asset ratio (24.06% in 2025) and competitive pressures in pharmaceuticals. The stock's current valuation at a P/E of 29.98 may limit near-term upside, but analyst optimism and dividend reliability support a positive outlook for patient investors.
KeyCorp (KEY) trades at $19.83, down 1.54% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The bank has beaten EPS estimates for three consecutive quarters, with a Q3 2026 estimate of $0.4615. Revenue rebounded to $7.29B in 2025, and the net income margin improved to 26.72%. Recent corporate actions include a $0.21 dividend and key executive appointments in wealth and retail banking.
The outlook is cautiously optimistic, supported by strong analyst consensus (60.79% buy rating) and a $25.00 price target implying 26% upside. Investment opportunities include earnings momentum and shareholder returns via dividends and buybacks. Risks involve interest rate sensitivity, competitive pressures on margins, and macroeconomic uncertainty affecting loan growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →
